Related Experiment Video

Updated: Jun 22, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Pharmacologic management of patients with both heart failure and diabetes

Michael R MacDonald1, Mark C Petrie, Miles Fisher

  • 1Department of Cardiology, Hairmyres Hospital, Eaglesham Road, East Kilbride, Glasgow G75 8RG, Scotland, United Kingdom. michael.macdonald@nhs.net

Current Heart Failure Reports
|June 3, 2009
PubMed

Insights

Managing diabetes and heart failure together requires careful consideration, as treatments for one condition can impact the other. This review clarifies evidence and dispels myths about pharmacologic management for patients with both diabetes and heart failure.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes and heart failure frequently coexist, significantly increasing patient morbidity and mortality risks.
  • Treatment decisions for each condition are complex due to potential contraindications and misconceptions.
  • Understanding the interplay between diabetes and heart failure management is crucial for optimal patient outcomes.

Purpose of the Study:

  • To clarify the evidence-based treatment strategies for patients with concurrent diabetes and heart failure.
  • To address and dispel common myths regarding pharmacologic management in this dual-diagnosis population.
  • To provide guidance on the safe and effective use of medications for both conditions.

Main Methods:

  • Systematic review of current medical literature.
  • Analysis of clinical trial data and treatment guidelines.
  • Expert consensus on pharmacologic interventions.

Main Results:

  • Identified specific diabetes medications with proven safety and efficacy in heart failure patients.
  • Clarified which heart failure therapies are safe and beneficial for individuals with diabetes.
  • Addressed contraindications and potential drug interactions.

Conclusions:

  • Evidence supports the use of certain pharmacologic agents for diabetes in heart failure patients.
  • Dispelling myths allows for more effective and safer treatment regimens.
  • Integrated management is essential for improving prognosis in patients with both conditions.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...